Table 5.

Comparison of disease characteristics at the end of the study between patients with or without event during the study. Data are n (%) unless otherwise indicated.

CharacteristicsNo EventEventpOR (95% CI)
Age, yrs, ± SD (n)57.6 ± 13.3 (430)70.7 ± 12.1 (34)< 0.0011.08 (1.05–1.11)
Duration PsA, yrs, ± SD (n)19.9 ± 10.9 (430)14.0 ± 13.5 (33)0.0040.94 (0.90–0.98)
Duration PsO, yrs, ± SD (n)29.5 ± 15.0 (407)31.2 ± 21.5 (31)0.5651.01 (0.98–1.03)
BMI, kg/m2, ± SD (n)27.7 ± 5.2 (273)27.8 ± 4.5 (27)0.8721.01 (0.93–1.08)
DAI, mean, ± SD (n)3.90 ± 0.85 (420)4.24 ± 1.02 (34)0.0301.47 (1.04–2.08)
Male215 (50)19 (56)0.510.79 (0.39–1.59)
Smoking (ever)226 (54)22 (67)0.161.70 (0.08–3.59)
Hypertension179 (42)26 (76)< 0.0014.5 (1.99–10.2)
Hyperlipidemia61 (14)10 (29)0.0192.5 (1.14–5.49)
Diabetes49 (12)9 (27)0.0082.89 (1.27–6.58)
Destructive/deforming disease216 (51)17 (50)0.940.97 (0.48–1.96)
bDMARD (ever)56 (13)1 (2.9)0.0830.20 (0.03–1.5)
sDMARD (ever)288 (67)24 (71)0.671.18 (0.55–2.54)
NSAID (ever)314 (73)13 (38)< 0.0010.23 (0.11–0.47)
Oral corticosteroids (ever)128 (30)15 (44)0.0831.86 (0.91–3.77)
Fulfilling CASPAR criteria387 (90)31 (91)0.861.12 (0.33–3.83)
Polyarthritis (according to Moll and Wright)*180 (42)17 (50)0.361.39 (0.69–2.79)
Dactylitis (ever)119 (40)10 (38)0.850.92 (0.41–2.11)
Nail involvement (ever)168 (53)10 (40)0.200.58 (0.25–1.34)
Axial involvement74 (17)5 (15)0.700.83 (0.31–2.21)
Axial and peripheral joint involvement41 (9.6)5 (15)0.331.63 (0.60–4.44)
  • * Moll and Wright criteria for PsA. PsA: psoriatic arthritis; PsO: psoriasis; BMI: body mass index; DAI: disease activity index; DMARD: disease-modifying antirheumatic drug; bDMARD: biological DMARD; sDMARD: synthetic DMARD; NSAID: nonsteroidal antiinflammatory drug; CASPAR: ClASsification for Psoriatic ARthritis (criteria).